Prognostic Value of Soluble Tumor Necrosis Factor Receptors 1 and 2 in Multiple Sclerosis Patients Treated with Interferon Beta-1b
| Autor: | C. Laske, N. Chatzimanolis, Joerg Kraus, H. Diehl, J. Tofighi, H Traupe, B. S. Kühne, T. Bregenzer, Manfred Kaps, Patrick Oschmann, R. Bauer |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male medicine.medical_specialty Pathology Multiple Sclerosis medicine.medical_treatment Gastroenterology Drug Administration Schedule Receptors Tumor Necrosis Factor Central nervous system disease Disability Evaluation Antigens CD Internal medicine medicine Humans Receptors Tumor Necrosis Factor Type II Prospective Studies Prospective cohort study Chemotherapy Dose-Response Relationship Drug medicine.diagnostic_test business.industry Multiple sclerosis Interferon beta-1b Interferon beta-1a Brain Magnetic resonance imaging Interferon-beta Prognosis medicine.disease Magnetic Resonance Imaging Cytokine Neurology Female Neurology (clinical) business medicine.drug |
| Zdroj: | European Neurology. 46:210-214 |
| ISSN: | 1421-9913 0014-3022 |
| DOI: | 10.1159/000050807 |
| Popis: | The objective of this study was to investigate the effect of interferon (IFN) beta-1b on the serum levels of soluble tumor necrosis factor receptor 1 (sTNF-R1) and sTNF-R2 in patients with multiple sclerosis (MS) in correlation with clinical and magnetic resonance image (MRI) activity. Serum samples were obtained every 3 months from 24 patients treated with 8 × 106 U of IFN beta-1b every other day (treatment group) and from 21 patients without any immunomodulatory therapy (control group) over a 15-month observation period. The cytokine receptor levels were assessed by ELISA. Cranial MRI was performed every 6 months to determine the burden of disease. In the treatment group, the MRI responders had significantly larger mean values for the area under the concentration-time curve of sTNF-R1 (p = 0.04) and sTNF-R2 (p = 0.01) when compared to the MRI nonresponders during the 15-month observation period. With regard to an increase in sTNF-R1 and -2 of more than 20% during the first 3 months of treatment, we observed a sensitivity of 33 and 58%, respectively, a specificity of 90 and 60%, respectively, and a positive predictive value of 80 and 64%, respectively, for MRI response during the 15-month observation period. A decrease in sTNF-R1 and -2 of more than 20% during the first 3 months of treatment had a sensitivity of 40 and 20%, respectively, a specificity of 100 and 100%, respectively, and a positive predictive value of 100 and 100%, respectively, for further MRI nonresponse (during the 15-month observation period). The present data suggest that assessment of sTNF-Rs may contribute to the identification of subgroups of patients who are likely to respond better than others to treatment with IFN beta-1b. This could help to establish a cost-effective prescription pattern for this expensive treatment, which is of importance for the future management of patients with MS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|